Press Releases

Oasmia has completed a private placement of new convertible instruments in a total amount of SEK 26,000,000

Oasmia Pharmaceutical AB (publ) (“Oasmia” or the “Company”) hereby announces that the Company has completed a private placement of a convertible loan in the amount of SEK 26,000,000 with an in...

Oasmia Pharmaceutical AB (publ)

Interim report for the period May 2017 – January 2018 Commercial focus and lower cost base

Oasmia Pharmaceutical’s Docecal program achieves significant development milestone

Oasmia Pharmaceutical AB announces that all patients have been treated in the two ongoing studies with Docecal in metastatic breast cancer.

Directed issue of warrants in Oasmia Pharmaceutical AB

The board of directors of Oasmia Pharmaceutical AB (publ) (“Oasmia” or the ”Company”) has resolved on a directed issue of no more than 34,838,709 warrants. Subsequently, all warrants have been...

Oasmia Pharmaceutical Secures Financing of 108 MSEK

Oasmia Pharmaceutical AB (publ) (“Oasmia” or the ”Company”) a developer of a new generation of drugs within human and veterinary oncology, has agreed to a loan totalling 108 million SEK, of w...

Oasmia Pharmaceutical receives marketing approval for Paclical® in Kazakhstan

Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, announced today that it has received marketing approval for Paclical in Kazakhst...

Oasmia has completed a private placement of new convertible instruments in a total amount of SEK 28,000,000

Oasmia Pharmaceutical AB (publ) (“Oasmia” or the “Company”) hereby announces that the Company has completed a private placement of a convertible loan in the amount of SEK 28,000,000 with an in...

Oasmia Pharmaceutical AB Announces Resignation of its Chief Financial Officer

Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology has announced that the Company’s Chief Financial Officer, Fredrik Gynnerstedt, ...

Nexttobe Extends Loan to Oasmia Pharmaceutical

Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology announced today that Nexttobe AB has extended its loan to the company. The cur...